Idiopathic pulmonary fibrosis: An update

QJM: An International Journal of Medicine

Volumn 99, Issue 10, 2006, Pages 643-654

  Dempsey, Owen J ^a   Kerr, K M ^a   Gomersall, L ^a   Remmen, H ^a   Currie, G P ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; BENZODIAZEPINE; BISPHOSPHONIC ACID DERIVATIVE; BOSENTAN; CALCIUM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DALTEPARIN; ETANERCEPT; GAMMA1B INTERFERON; IMATINIB; METHYLPREDNISOLONE; OPIATE; OXYGEN; PIRFENIDONE; PREDNISOLONE; PREDNISONE; VITAMIN D; WARFARIN;

CHRONIC LUNG DISEASE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; COUGHING; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG MEGADOSE; DYSPNEA; EXERCISE TOLERANCE; HISTOPATHOLOGY; HUMAN; INTERSTITIAL PNEUMONIA; LUNG FIBROSIS; LUNG TRANSPLANTATION; MAXIMUM PERMISSIBLE DOSE; NONHUMAN; PALLIATIVE THERAPY; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY REHABILITATION; RADIODIAGNOSIS; REVIEW; SURVIVAL TIME;

EID: 33749612195     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcl098     Document Type: Review

References (75)

1. American Thoracic Society.diopathic pulmonary fibrosis: Diagnosis and treatment. International Consensus Statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161:646-64.
2. British Thoracic Society. The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Thorax 1999; 54(Suppl. 1):S1-14.
3. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165:277-304.
4. Swigris JJ, Kuschner WG, Jacobs SS, Wilson SR, Gould MK. Health-related quality of life in patients with idiopathic pulmonary fibrosis: A systematic review. Thorax 2005; 60:588-94.
5. Daniil ZD, Gilchrist FC, Nicholson AG, Hansell DM, Harris J, Colby TV, du Bois RM. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999; 160:899-905.
6. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, Flaherty KR, Schwartz DA, Noble PW, Raghu G, Brown KK; IPF Study Group. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142:963-7.
7. Panos RJ, Mortenson RL, Niccoli SA, King TE Jr. Clinical deterioration in patients with idiopathic pulmonary fibrosis: Causes and assessment. Am J Med 1990; 88:396-404.
8. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994; 150:967-72.
9. Hubbard R, Johnston I, Coultas DB, Britton J. Mortality rates from cryptogenic fibrosis alveolitis in seven countries. Thorax 1996; 51:711-16.
10. Leslie KO. Pathology of interstitial lung disease. Clin Chest Med 2004; 25:657-703.
11. Corrin B, Dewar A, Rodriguez-Roisin R, Turner-Warwick M. Fine structural changes in cryptogenic fibrosing alveolitis and asbestosis. J Pathology 1985; 147:107-19.
12. Basset F, Ferrans VJ, Soler P, Takemura T, Fukuda Y, Crystal RG. Intraluminal fibrosis in interstitial lung disorders. Am J Pathol 1986; 122:433-61.
13. Noble PW, Homer RJ. Back to the future: Historical perspective on the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2005; 33:113-20.
14. Selman M, Thannickal VJ, Pardo A, Zisman DA, Martinez FJ, Lych JP 3rd. Idiopathic pulmonary fibrosis: Pathogenesis and therapeutic approaches. Drugs 2004; 64:405-30.
15. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, Belperio JA, Keane MP, Strieter RM. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004; 114:438-46.
16. Garantziotis S, Steele MP, Schwartz DA. Pulmonary fibrosis; thinking outside of the lung. J Clin Invest 2004; 114:319-21.
17. Strieter RM. Pathogenesis and natural history of usual interstitial pneumonia: The whole story or the last chapter of a long novel. Chest 2005; 128:526-32S.
18. Keane MP, Arenberg DA, Lynch JP 3rd, White RI, Iannettoni MD, Burdick MD, Wilke CA, Morris SB, Glass MC, DiGiovine B, Kunkel SL, Strieter RM. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997; 159:1437-43.
19. Strieter RM, Starko KM, Enelow RI, Noth I, Valentine VG; Idiopathic Pulmonary Fibrosis Biomarkers Study Group. Effects of interferon-gamma 1b on biomarker expression in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004; 170:133-40.
20. Burdick MD, Murray LA, Keane MP, Xue YY, Zisman DA, Belperio JA, Strieter RM. CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am J Respir Crit Care Med 2005; 171:261-8.
21. Grutters JC, du Bois RM. Genetics of fibrosing lung diseases. Eur Respir J 2005; 25:915-27.
22. Marney A, Lane KB, Phillips JA 3rd, Riley DJ, Loyd JE. Idiopathic pulmonary fibrosis can be an autosomal dominant trait in some families. Chest 2001; 120:565.
23. Marshall RP, Puddicombe A, Cookson WO, Laurent GJ. Adult familial cryptogenic fibrosis alveolitis in the United Kingdom. Thorax 2000; 55:143-6.
24. Hodgson U, Laitinen T, Tukiainen P. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: Evidence of founder effect among multiplex families in Finland. Thorax 2002; 57:338-42.
25. Lawson WE, Grant SW, Ambrosini V, Womble KE, Dawson EP, Lane KB, Markin C, Renzoni E, Lympany P, Thomas AQ, Roldan J, Scott TA, Blackwell TS, Phillips JA 3rd, Loyd JE, du Bois RM. Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. Thorax 2004; 59:977-80.
26. Flaherty KR, King TE Jr, Raghu G, Lynch JP 3rd, Colby TV, Travis WD, Gross BH, Kazerooni EA, Toews GB, Long Q, Murray S, Lama VN, Gay SE, Martinez FJ. Idiopathic interstitial pneumonia: What is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med 2004; 170:904-10.
27. Strange C, Highland KB. Interstitial lung disease in the patient who has connective tissue disease. Clin Chest Med 2004; 25:549-59.
28. Lama VN, Flaherty KR, Toews GB, Coby TV, Travis WD, Long Q, Murray S, Kazerooni EA, Gross BH, Lych JP 3rd, Martinez FJ. Prognostic value of desaturation during a 6-min walk in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168:1084-90.
29. Hallstrand TS, Boitano LJ, Johnson WC, Spada CA, Hayes JG, Raghu G. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur Respir J 2005; 25:96-103.
30. Eaton T, Young P, Milne D, Wells AU. Six-minute walk, maximal exercise tests: Reproducibility in fibrotic interstial pneumonia. Am J Respir Crit Care Med 2005; 171:1150-7.
31. Epler GR, McLoud TC, Gaensler EA, Mikus JP, Carrington CB. Normal chest roentgenograms in chronic diffuse infiltrative lung disease. N Engl J Med 1978; 298:934-9.
32. Lynch DA, Travis WD, Muller NL, Galvin JR, Hansell DM, Grenier PA, King TE Jr. Idiopathic interstitial pneumonias: CT features. Radiology 2005; 236:10-21.
33. Monaghan H, Wells AJ, Colby TB, du Bois RM, Hansell DM, Nicholson AG. Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias. Chest 2004; 125:522-6.
34. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwartz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168:538-42.
35. Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, Travis WD, Flint A, Toews GB, Lynch JP 3rd, Martinez FJ. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168:543-8.
36. Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, Veeraraghavan S, Hansell DM, Wells AU. Fibrotic idiopathic interstitial pneumonia; the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168:531-7.
37. Egan JJ, Martinez FJ, Wells AU, Williams T. Lung function estimates in idiopathic pulmonary fibrosis: The potential for a simple classification. Thorax 2005; 60:270-3.
38. Flaherty KR, Thwaite EL, Kazerooni EA, Gross BH, Toews GB, Colby TV, Travis WD, Mumford JA, Murray S, Flint A, Lynch JP 3rd, Martinez FJ. Radiological versus histological diagnosis in UIP and NSIP: Survival implications. Thorax 2003; 58:143-8.
39. Strange C, Highland KB. Pulmonary hypertension in interstitial lung disease. Curr Opin Pul Med 2005; 11:452-5.
40. Nadrous HF, Pellikka P, Krowka MJ, Swanson KL, Chaowalit N, Decker PA, Ryu JH. The impact of pulmonary hypertension on survival in patients with idiopathic pulmonary fibrosis. Chest 2005; 128:616-17S.
41. Davies HR, Richeldi L, Walters EH. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003; 3:CD003134.
42. Flaherty KR, Toews GB, Lynch JP 3rd, Kazerooni EA, Gross BH, Strawderman RL, Hariharan K, Flint A, Martinez FJ. Steroids in idiopathic pulmonary fibrosis: A prospective assessment of adverse reactions, response to therapy, and survival. Am J Med 2001; 110:278-82.
43. British Thoracic Society Working Group on Home Oxygen Services. Clinical component for the home oxygen service in England and Wales. [http://www.brit-thoracic.org.uk]. Accessed 25 March 2006.
44. Harris-Eze AO, Sridhar G, Clemens RE, Gallagher CG, Marciniuk DD. Oxygen improves maximal exercise performance in interstitial lung disease. Am J Respir Crit Care Med 1994; 150:1616-22.
45. Caplan-Shaw CE, Arcasoy SM, Shane E, Lederer DJ, Wilt JS, O'Shea MK, Addesso V, Sonett JR, Kawut SM. Osteoporosis in diffuse parenchymal lung disease. Chest 2006; 129:140-6.
46. American College of Rheumatology.Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001; 44:1496-503.
47. British Thoracic Society Standards of Care Subcommittee on Pulmonary Rehabilitation.Pulmonary rehabilitation. Thorax 2001; 56:827-34.
48. Nathan SD. Lung transplantation: Disease-specific considerations for referral. Chest 2005; 127:1006-16.
49. The International Society for Heart and Lung Transplantation. Heart/Lung Transplant Registry. [http://www.ishlt.org/registries/ slides.asp?slides=heartLungRegistry]. Accessed 8 March 2006.
50. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, Flaherty KR, Schwartz DA, Noble PW, Raghu G, Brown KK; IPF study group. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142:963-7.
51. Akira M, Hamada H, Sakatani M, Kobayashi C, Nishioka M, Yamamoto S. CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. Am J Roentgenol 1997; 168:79-83.
52. Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic finding in three cases. Chest 1993; 103:1808-12.
53. Ambrosini V, Cancellieri A, Chilosi M, Zompatori M, Trisolini R, Saragoni L, Poletti V. Acute exacerbation of idiopathic pulmonary fibrosis: Report of a series. Eur Respir J 2003; 22:821-6.
54. Saydain G, Islam A, Afessa B, Ryu JH, Scott JP, Peters SG. Outcome of Patients with idiopathic pulmonary fibrosis admitted to the Intensive Care Unit. Am J Respir Crit Care Med 2002; 166:839-42.
55. Thannickal VJ, Flaherty KR, Hyzy RC, Lynch JP 3rd. Emerging drugs for idiopathic pulmonary fibrosis. Expert Opin Emerg Drugs 2005; 10:707-27.
56. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, Sato A, Kudoh S. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171:1040-7.
57. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE Jr; Idiopathic Pulmonary Fibrosis Group. A placebo controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350:125-33.
58. MacNee W, Rahman I. Oxidants/antioxidants in idiopathic pulmonary fibrosis. Thorax 1995; 50(Suppl. 1):S53-8.
59. Cantin AM, Hubbard RC, Crystal RG. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1989; 139:370-2.
60. Demedts M, Behr J, Buhl R, et al.; the IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353:2229-42.
61. Magro CM, Allen J, Pope-Harman A, Waldman WJ, Moh P, Rothrauff S, Ross P Jr. The role of microvascular injury in the evolution of idiopathic pulmonary fibrosis. Am J Clin Path 2003; 119:556-67.
62. Gagermeier J, Dauber J, Yousem S, Gibson K, Kaminski N. Abnormal vascular pheotypes in patients with idiopathic pulmonary fibrosis and secondary pulmonary hypertension. Chest 2005; 128:601S.
63. Kubo H, Nakayama K, Yanai M, Suzuki T, Yamaya M, Watanable M, Sasaki H. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128:1475-82.
64. Giaid A, Michel RP, Stewart DJ, Sheppard M, Corrin B, Hamid Q. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 1993; 341:1550-4.
65. Park SH, Saleh D, Giaid A, Michel RP. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 1997; 156:600-8.
66. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896-903.
67. Kapanci Y, Desmouliere A, Pache JC, Redard M, Gabbiani G. Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis. Possible role of transforming growth factor beta and tumor necrosis factor alpha. Am J Respir Crit Care Med 1995; 152:2163-9.
68. Piguet PF, Kaufman S, Barazzone C, Muller M, Ryffel B, Eugster HP. Resistance of TNF/LT alpha double deficient mice to bleomycin-induced fibrosis. Int J Exp Pathol 1997; 78:43-8.
69. Piguet PF, Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Resp J 1994; 7:515-18.
70. Zhang Y, Lee TC, Guillemin B, Yu MC, Rom WN. Enhanced IL-1 beta and tumor necrosis factor-alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J Immunol 1993; 150:4188-96.
71. Piguet PF, Ribaux C, Karpuz V, Grau GE, Kapanci Y. Expression and localization of tumour necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis. Am J Pathol 1993; 143:651-5.
72. Whyte M, Hubbard R, Meliconi R, Whidborne M, Eaton V, Bingle C, Timms J, Duff G, Facchini A, Pacilli A, Fabbri M, Hall I, Britton J, Johnston I, Di Giovine F, et al. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms. Am J Respir Crit Care Med 2000; 162:755-8.
73. Niden A, Koss M, Boylen CT, Wilcox A. An open label pilot study to determine the potential efficacy of TNFR:FC (Enbrel, Etanercept) in the treatment of usual interstitial pneumonitis. Am J Respir Crit Care Med 2002; 165:A728.
74. Savage DG, Antman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002; 346:683-93.
75. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, Leof EB. Imatinib mesylate inhibits the profibrogenc activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004; 114:1308-16.